文献速递细胞病理与分子病理神经与头颈病理

PD-L1在甲状腺细胞学中的诊断与预后价值

PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
PubMed 文献 · Cancer Cytopathol · 2019-12-10

该研究对236例甲状腺细针穿刺细胞学(FNAC)样本进行PD-L1免疫染色,并在相应组织学样本上验证。结果显示PD-L1表达见于79例(38.5%),包括61例甲状腺乳头状癌(PTC),而在NIFTP和滤泡腺瘤中均为阴性。PD-L1阳性恶性肿瘤中15%存在BRAF V600E突变,提示PD-L1可能作为恶性肿瘤及侵袭性行为的标志物。

要点

  • PD-L1在甲状腺PTC中高表达,在NIFTP和滤泡腺瘤中不表达。
  • PD-L1阳性甲状腺肿瘤中15%伴有BRAF V600E突变。
  • PD-L1免疫染色可用于液基细胞学辅助鉴别甲状腺病变良恶性。

核心结论

  • 甲状腺PD-L1表达可能是与PTC相关的恶性肿瘤标志物,但与NIFTP无关。
  • PD-L1阳性甲状腺肿瘤富集BRAF V600E突变,提示与更具侵袭性行为相关。

研究设计与样本

  • 回顾性纳入2018年1月至2019年3月236例甲状腺FNAC样本,诊断类别为不确定病变、可疑恶性(SFM)和恶性。
  • 在液基细胞学(LBC)和对应组织学样本上进行PD-L1免疫染色。

主要发现

  • FNAC队列包括50例良性阴性对照、42例AUS/FLUS、33例FN/SFN、53例SFM和58例恶性样本。
  • 79例(38.5%)显示血浆膜和细胞质PD-L1表达增加,包括61例PTC(经典型及变异型)。
  • NIFTP和滤泡腺瘤中PD-L1表达为阴性。
  • PD-L1阳性恶性肿瘤中15%检出BRAF V600E突变。

临床怎么用

  • PD-L1免疫染色可辅助FNAC鉴别甲状腺病变良恶性,尤其提示PTC可能。
  • PD-L1阳性结果或可提示BRAF V600E突变及更具侵袭性的生物学行为。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is emerging as an important predictive biomarker in anti-PD-L1 cancer immunotherapy. Its role has been clearly defined in various human cancers and is linked to a poor prognosis and resistance to anticancer therapies. The role of PD-L1 in thyroid cancers has not been well defined in fine-needle aspiration cytology (FNAC). The authors examined the performance of PD-L1 immunostaining in liquid-based cytology (LBC) to determine whether it could be a biomarker of malignancy or aggressive disease. METHODS: From January 2018 to March 2019, 236 thyroid lesions, which had been diagnosed by FNAC as indeterminate lesions, suspicious for malignancy (SFM), and malignant, were enrolled. PD-L1 immunostaining was performed on both LBC and corresponding histology samples. RESULTS: The FNAC cohort included 50 benign negative controls, 42 samples of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 33 samples of follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), 53 samples that were suspicious for malignancy (SFM), and 58 malignant samples. AUS/FLUS samples included 3 goiters, 32 follicular adenomas (FAs), 1 noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), 5 invasive follicular variants of papillary thyroid carcinoma (I-FVPTCs), and 1 follicular carcinoma; whereas FN/SFN samples included 24 FAs and 9 malignancies (4 I-FVPTCs, 1 NIFTP, 3 papillary thyroid carcinomas [PTCs], and 1 oncocytic follicular carcinoma). The 53 SFM samples were diagnosed on histopathology as 2 FAs, 5 NIFTPs, 15 I-FVPTCs, and 31 PTCs; whereas the 58 malignant specimens included 5 NIFTPs, 5 I-FVPTCs, and 48 PTCs. Increased plasma membrane and cytoplasmic PD-L1 expression was found in 79 cases (38.5%), including 61 PTCs (conventional and variants). Negative PD-L1 expression was found in NIFTPs and FAs. A BRAF V600E mutation was identified in 15% of PD-L1-positive malignancies. CONCLUSIONS: The current data suggest that PD-L1 expression in the thyroid gland might represent a marker of malignancy that correlates with PTC, but not with NIFTP. Thyroid neoplasms with PD-L1 expression also ae enriched with BRAF V600E mutations, suggesting that they are associated with more aggressive behavior.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Dell'Aquila M, Granitto A, Martini M, et al. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker. Cancer Cytopathol. 2019. PMID: 31821747. doi:10.1002/cncy.22224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。